Newamsterdam Pharma Company N v (NAMS) - News Archive

Unlocking Cardiovascular Breakthroughs: NewAmsterdam Pharma s Promising DevelopmentsNewAmsterdam Pharma, a late-stage clinical biopharmaceutical company, has captured the attention of the scientific community with its r...

Interpreting NewAmsterdam Pharma s Strategic Inducement Grants: Implications for Shareholder Value and Future GrowthIn a significant strategic move, NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), a late-stage clinical...

NewAmsterdam Pharma Looks Forward Amidst Financial Losses and Promising Cardiovascular ResearchBy CSI MarketAs NewAmsterdam Pharma Company N.V. strides into 2025, the company s ambitions remain remarkably high despite t...

In an industry where innovation and talent acquisition go hand-in-hand, NewAmsterdam Pharma Company N.V. a trailblazer in cardiovascular treatments, has once again fortified its ranks with an assertive move. The Netherl...

: The management of cardiovascular disease (CVD) remains a predominant challenge in modern medicine, particularly among patients who exhibit elevated levels of low-density lipoprotein cholesterol (LDL-C) and for whom ex...

NewAmsterdam Pharma Announces Closing of $479.0 Million Upsized Public Offering, Expanding Resources for Cardiovascular Disease InnovationsIn a significant stride towards enhancing its financial capabilities and expandi...

NewAmsterdam Pharma Expands Capital Base with $416.5 Million Public Offering: A Strategic Move for Growth in Cardiovascular TreatmentsNewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), a late-stage, clinical biopharmaceut...

NewAmsterdam Pharma Announces Strategic Inducement Grants: A Step Towards Strengthening its Workforce and Shareholder ValueIn a recent press release from NewAmsterdam Pharma Company N.V. the late-stage biopharmaceutical...

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024 At the America...

In its quest to become a frontrunner in the fight against cardiovascular disease, NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), with headquarters in Naarden, The Netherlands, and Miami, has made significant strides i...

NewAmsterdam Pharma Strengthens Leadership to Accelerate Innovations in Cardiovascular TreatmentsIn a significant move reflecting its growth ambitions, NewAmsterdam Pharma Company N.V. a late-stage clinical biopharmaceu...

Summary:NewAmsterdam Pharma Company N.V. a leading clinical biopharmaceutical company based in the Netherlands, disclosed the approval of inducement grants for three non-executive new hires. These grants, intended to at...

: NewAmsterdam Pharma Company N.V., a clinical biopharmaceutical company focused on developing non-statin therapeutics for cardiovascular disease (CVD), continues to make significant strides in its research and corporat...

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia In a significant advancement in the tre...

: NewAmsterdam Pharma is set to announce topline data from its pivotal Phase 3 BROOKLYN clinical trial evaluating obicetrapib in patients with heterozygous familial hypercholesterolemia (HeFH) on July 29, 2024. This ann...

NewAmsterdam Pharma recently announced the successful completion of patient enrollment for its pivotal Phase 3 TANDEM clinical trial. This trial aims to evaluate the efficacy and safety of a fixed-dose combination of Ob...

NewAmsterdam Pharma Grants Inducement Share Options to New HiresNAARDEN, The Netherlands and MIAMI, July 03, 2024 - NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or NewAmsterdam), a leading clinical biopharmaceutical c...

NAARDEN, the Netherlands and MIAMI, June 07, 2024 NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), an advanced-stage clinical biopharmaceutical company, has made a significant stride in bolstering its workforce. The com...

NewAmsterdam Pharma Grants Inducement Share Options to Non-Executive New HiresNewAmsterdam Pharma Company N.V., a clinical biopharmaceutical company based in the Netherlands and Miami, has recently approved the grant of...

NewAmsterdam Pharma, a pioneering pharmaceutical company, has successfully enrolled over 9,000 patients in the highly anticipated Phase 3 PREVAIL Global Cardiovascular Outcome Trial. This pivotal study aims to evaluate...